Evaluate Vantage
J.P. Morgan Health Care Conference
Evaluate Vantage®
ARTICLE PACK DOWNLOAD
Highlights from the 40th Annual J.P. Morgan Health Care Conference
Evaluate Vantage provided comprehensive coverage of the 40th Annual J.P. Morgan Health Care Conference, held virtually from 10 to 13 January.
This article pack rounds up our key takeaways and data-driven insights. Access your complimentary copy now and delve into the most important news, breakthroughs and developments unveiled at the event.
WHAT’S IN THE PACK?
Biogen hints at jobs cuts unless government pays up:
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
Abbvie looks to crack the cystic fibrosis code:
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex's monopoly.
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex's monopoly.
Aduhelm verdict puts the heat on Biogen - and on the FDA:
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Infinity beckons for Illumina:
A specialist in sequencing short strands of DNA, Illumina is working on a new long-read technology, codenamed 'Infinity'.
A specialist in sequencing short strands of DNA, Illumina is working on a new long-read technology, codenamed 'Infinity'.
Sarepta gets another bite at the gene therapy cherry:
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
JP Morgan 2022 roundup - Biogen in focus:
Much of this week's business development might be done and dusted, but for Biogen things are just warming up.
Much of this week's business development might be done and dusted, but for Biogen things are just warming up.
JP Morgan 2022 - Day one sees healthy deal flow from biopharma:
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Beam and Mammoth hook big pharma partners:
Beam signs Pfizer up for $300m up front, while Mammoth's deal with Bayer is worth a more modest $40m.
Beam signs Pfizer up for $300m up front, while Mammoth's deal with Bayer is worth a more modest $40m.
A late Christmas present for Allogene:
US clinical hold over Allogene's entire pipeline has just been lifted.
US clinical hold over Allogene's entire pipeline has just been lifted.
